NCT05308680 is a clinical trial of BNT162b2 in Myocardial Injury, sponsored by Shaare Zedek Medical Center.

Who is sponsoring NCT05308680?

NCT05308680 is sponsored by Shaare Zedek Medical Center.

What drugs are being tested in NCT05308680?

Interventions in NCT05308680: BNT162b2.

What condition does NCT05308680 study?

NCT05308680 studies Myocardial Injury, Vaccine Adverse Reaction, COVID-19.

Is NCT05308680 still recruiting?

NCT05308680 is currently completed. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT05308680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers

Completed Last updated 9 May 2022

What this trial tests

trial testing BNT162b2 in Myocardial Injury in 336 participants. Completed in 28 March 2022.

Timeline

6 January 2022

Primary endpoint
24 January 2022

28 March 2022

Quick facts

Lead sponsor	Shaare Zedek Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	336
Start date	6 January 2022
Primary completion	24 January 2022
Estimated completion	28 March 2022
Sites	1 location across Israel

Drugs / interventions tested

BNT162b2 (bnt162b2) — full drug profile →

Conditions studied

Myocardial Injury — all drugs for Myocardial Injury →
Vaccine Adverse Reaction — all drugs for Vaccine Adverse Reaction →
COVID-19 — all drugs for COVID-19 →

Sponsor

Shaare Zedek Medical Center

Who can join

18 and older, any sex, with Myocardial Injury or Vaccine Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda VP, Jogi G, Dave S, Patel BM, et al · · 2023 · cited 15× · PMID 36992091 · DOI 10.3390/vaccines11030507
A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
Levi N, Moravsky G, Weitsman T, Amsalem I, et al · · 2023 · cited 8× · PMID 36097844 · DOI 10.1002/ejhf.2687

Verify or expand the search:

Other trials of BNT162b2

Trials testing the same drug.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05621239 — A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People · completed
NCT05343871 — Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase · Phase 4 · completed
NCT05310084 — Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age · Phase 3 · completed
NCT05289037 — COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) · Phase 2 · completed

Other recruiting trials for Myocardial Injury

Currently open trials in the same condition.

NCT06982404 — ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biop · recruiting
NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
NCT06954103 — Mechanisms And Prognosis of Stroke-Heart Syndrome · recruiting
NCT06705023 — Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an · Phase 2 · recruiting
NCT06296212 — Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial In · Phase 3 · recruiting

Other Shaare Zedek Medical Center trials

Trials by the same sponsor.

NCT05331209 — Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers · NA · not yet recruiting
NCT06070753 — A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Str · NA · unknown
NCT05841953 — The Use of Electrical Stimulation to Increase Anal Pressures · NA · unknown
NCT06777706 — Open Label Study to Assess Safety & Efficacy of QD for Induction of Remission in Pediatric Patients with UC · NA · completed
NCT05838105 — Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05308680 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shaare Zedek Medical Center
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05308680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing